Cannabis Operator Cresco Down 28.5% YTD: How to Play the Stock?
CRLBF is down 28.5% YTD as revenue pressure and competition persist, but retail expansion and improving estimates could shape its next move.
Zacks
More News
MSOS Hits 2026 High: Which Cannabis Stock Could Light Up Portfolios Ahead Of DEA Hearing?
The cannabis ETF has surged 104% over the past year, outperforming both the North American Marijuana Index and the S&P 500.
Stocktwits
Verano Advances U.S. Exchange Uplisting Plans: Time to Invest?
VRNO's reverse split and prior U.S. redomestication support potential exchange uplisting plans as the company expands stores and product offerings.
Zacks
Curaleaf Prepares for US Exchange Uplisting: Time to Invest?
CURLF's reverse stock split and Delaware domestication plan signal preparation for a potential U.S. uplisting as revenue and international growth improve.
Zacks
Schedule III for Some, Not All: Understanding the DOJ's Cannabis Shift
DOJ narrows cannabis reform, shifting select marijuana products to Schedule III while leaving broader federal restrictions intact.
Zacks
Green Thumb Industries Inc. (GTBIF) Moves 10.0% Higher: Will This Strength Last?
Green Thumb Industries Inc. (GTBIF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
Weedcoin Jumps In Minutes After Trump’s Marijuana Shake-Up Speculation Sparks Sector Frenzy
Cannabis stocks and ETFs rallied sharply, with names like TLRY, GTBIF, TCNNF, and IIPR jumping 6% to over 20% in midday trade.
Stocktwits
Curaleaf Launches Buyback Program: Time to Get Bullish on the Stock?
CURLF's $83M buyback lifts shares, but U.S. pricing pressure and rising losses cloud the outlook despite strong international growth momentum.
Zacks
Boston Scientific (BSX) Q1 Earnings Match Estimates
Boston Scientific (BSX) delivered earnings and revenue surprises of +0.59% and +0.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Cannabis Operator GTBIF Stock Down 17% YTD: Should You Buy the Dip?
Green Thumb has lost 17% YTD as pricing pressure and competition weigh, but steady revenue growth and strong cash flow raise the question: Is the dip worth buying?